Q3 sales met the consensus estimates, although the fact that the management maintained its 2023 guidance perhaps disappointed investors. Barring biosimilar erosion for off-patent drugs, all therapeutic areas performed well, however falling COVID-19-related demand weighed on Diagnostics’ sales. While Roche’s shares have fallen out of favour of late, largely owing to near-medium term growth concerns, the management needs to flex its robust balance sheet to address these issues, so that Roche’s att ....
